계명대학교 의학도서관 Repository

Current treatment patterns within 1 year after prostate cancer diagnosis in Korean patients over 75 years old: a retrospective multicenter study

Metadata Downloads
Author(s)
Dong Jin ParkHo Won KangSe Yun KwonYoung Jin SeoKyung Seop LeeByung Hoon KimTeak Jun ShinWon Tae KimYong-June KimSeok Joong YunSang-Cheol LeeJae-Wook ChungSeock Hwan ChoiJun Nyung LeeHyun Tae KimTae-Hwan KimEun Sang YooTae Gyun KwonWonho JungYun-Sok Ha
Keimyung Author(s)
Lee, Kyung SeopKim, Byung HoonShin, Teak JunJung, Won Ho
Department
Dept. of Urology (비뇨의학)
Journal Title
Prostate Int
Issued Date
2023
Volume
11
Issue
1
Keyword
AgingProstate CancerTreatment
Abstract
Background:
We aimed to evaluate the current status of first-line treatment options for prostate cancer in patients aged ≥75 years in Korea.

Materials and methods:
The study included 873 patients diagnosed with biopsy-proven prostate cancer at 5 institutions in Korea from January 2009 to December 2018. Inclusion criteria were aged ≥75 years at diagnosis, prostate biopsy with ≥12 cores, and follow-up period ≥1 year. Clinical data were retrospectively collected from electronic medical records.

Results:
Primary treatment for prostate cancer in patients aged ≥75 years included androgen deprivation therapy (ADT) (n = 614), radical prostatectomy (RP) (n = 114), and radiation therapy (n = 62). Among patients with RP, nine patients received ADT before RP. The RP group was younger with better Eastern Cooperative Oncology Group Performance Status (ECOG PS), lower initial prostate-specific antigen (PSA), Gleason score (GS), max percent positive cores, less positive cores, and less advanced clinical Tumor Node Metastasis (TNM) stage compared with the ADT group. Multivariate analysis showed that age, ECOG PS, and PSA were independent prognostic factors for RP. When the ADT group was classified by therapeutic regimens, the most common therapeutic regimen was maximal androgen blockade (MAB) (n = 571), and leuprolide + bicalutamide (n = 330) was the most common MAB regimen. Multivariate analysis for secondary treatment showed that age, ECOG PS, GS, and clinical N1 or M1 stage were independent predictive factors. Enzalutamide was the most preferred treatment for tertiary treatment.

Conclusion:
In patients with prostate cancer aged ≥75 years, the most common treatment option was MAB, and the leuprolide + bicalutamide was the most common MAB regimen. Age, ECOG PS, and PSA are the useful indicators of surgical treatment, which increased during the study period. Younger patients with high GS and advanced clinical stage were more likely to undergo secondary treatment.
Keimyung Author(s)(Kor)
이경섭
김병훈
신택준
정원호
Publisher
School of Medicine (의과대학)
Type
Article
ISSN
2287-8882
Source
https://www.sciencedirect.com/science/article/pii/S2287888222000472?via%3Dihub
DOI
10.1016/j.prnil.2022.08.003
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/45021
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Urology (비뇨의학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.